Synthesis of new N-(pyridin-3-ylmethyl)-2-aminothiazoline derivatives possessing anticholinesterase and antiradical activity as potential multifunctional agents for the treatment of neurodegenerative diseases


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

New N-(pyridin-3-ylmethyl)-2-aminothiazolines containing various substituents at the 5 position of the thiazoline ring and the 4-tert-butylbenzyl, 4-isopropylbenzyl, or 4-fluorobenzyl moiety at the nitrogen atom of the amino group were synthesized. The inhibitory activity of the synthesized compounds against human erythrocyte acetylcholinesterase (AChE, EC 3.1.1.7), equine serum butyrylcholinesterase (BChE, EC 3.1.1.8), and porcine liver carboxylesterase (CaE, EC 3.1.1.1) was evaluated and their antioxidant properties were studied by ABTS assay. N-(Pyridin-3-ylmethyl)-2-aminothiazolines proveded to be very weak AChE inhibitors, while their inhibitory activity against BChE and CaE was structure-dependent. 2-Aminothiazolines containing the 4-tert-butylbenzyl moiety are more efficient BChE inhibitors compared to the derivatives containing the 4-isopropylbenzyl or 4-fluorobenzyl substituent. An analysis of the dependence of the esterase profile of N-(pyridin-3-ylmethyl)-2-aminothiazolines on the structure of the substituent at the 5 position of the thiazoline ring of these compounds demonstrated that the derivatives containing the iodomethyl substituent possess the highest anti-BChE activity, the compounds with R2 = H and R3 = CH2I have the optimal esterase profile. Regardless of the structure of the substituents in the benzyl moiety, all N-(pyridin-3-ylmethyl)-2-aminothiazolines containing the iodomethyl substituent at the 5 position of the thiazoline ring exhibited high radical scavenging activity comparable with that of the standard antioxidant Trolox. N-(Pyridin-3-ylmethyl)-2-aminothiazolines were shown to be a new promising class of compounds for the design of multifunctional agents for the treatment of neurodegenerative diseases.

About the authors

G. F. Makhaeva

Institute of Physiologically Active Compounds, Russian Academy of Sciences

Author for correspondence.
Email: gmakh@ipac.ac.ru
Russian Federation, 1 Severnyi proezd, Chernogolovka, Moscow Region, 142432

T. P. Trofimova

Department of Chemistry, M. V. Lomonosov Moscow State University

Email: gmakh@ipac.ac.ru
Russian Federation, 1, Bld. 3, Leninskie Gory, Moscow, 119991

N. P. Boltneva

Institute of Physiologically Active Compounds, Russian Academy of Sciences

Email: gmakh@ipac.ac.ru
Russian Federation, 1 Severnyi proezd, Chernogolovka, Moscow Region, 142432

E. V. Rudakova

Institute of Physiologically Active Compounds, Russian Academy of Sciences

Email: gmakh@ipac.ac.ru
Russian Federation, 1 Severnyi proezd, Chernogolovka, Moscow Region, 142432

O. G. Serebryakova

Institute of Physiologically Active Compounds, Russian Academy of Sciences

Email: gmakh@ipac.ac.ru
Russian Federation, 1 Severnyi proezd, Chernogolovka, Moscow Region, 142432

S. V. Lushchekina

N. M. Emanuel Institute of Biochemical Physics, Russian Academy of Science

Email: gmakh@ipac.ac.ru
Russian Federation, 4 ul. Kosygina, Moscow, 119334

A. N. Proshin

Institute of Physiologically Active Compounds, Russian Academy of Sciences

Email: gmakh@ipac.ac.ru
Russian Federation, 1 Severnyi proezd, Chernogolovka, Moscow Region, 142432

S. O. Bachurina

Institute of Physiologically Active Compounds, Russian Academy of Sciences

Email: gmakh@ipac.ac.ru
Russian Federation, 1 Severnyi proezd, Chernogolovka, Moscow Region, 142432

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Springer Science+Business Media, LLC, part of Springer Nature